UNSPSC 51144122: Furfenorex

This classification denotes an anorexiant with the molecular formula C15H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) X83CZ0Y5TF, chemically known as 2-furanmethanamine, n-methyl-n-(1-methyl-2-phenylethyl)-, (+)- (9ci) but more generally known as furfenorex, which bears US NIH Compound Identifier 26762. European Medicines Agency schedules Furfenorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07840MIG.

UNSPSC 51144122 Furfenorex is a Commodity code, but the recent state and local procurement activity tagged under it does not reflect purchase of furfenorex itself. Instead, the opportunities listed show state and local governments procuring naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and actual solicitation activity suggests this code sees little relevant recent procurement aligned with its stated product definition. The three recent opportunities reflect broader pharmaceutical and pharmacy benefit management activity rather than furfenorex as a line item. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local governments across multiple states including Oregon).

Recent activity is concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with electronic bid submission and shipping included in proposals. Texas HHS Commission posted an RFI (HHS0017013, response due April 3, 2026) exploring direct-to-manufacturer prescription programs for its pharmacy benefit initiative. Minnesota's cooperative purchasing alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with awards effective July 1, 2026 and contract terms of two years. The code shows minimal specific activity around furfenorex procurement; vendors evaluating this code should assess whether pharmaceutical distribution, pharmacy benefit management, or drug deactivation systems align with their service lines rather than assume furfenorex demand.